Eisner Mark 4

What Happened
Mark Eisner, a director of Zura Bio Ltd (ZURA), received a derivative award on June 17, 2026: 51,000 shares reported as acquired at $0.00 (total reported value $0). This was a compensatory option/award grant (not an open-market purchase or sale) and does not represent an immediate cash transaction or share sale.

Key Details

• Transaction date: 2026-06-17; Form 4 filed: 2026-06-22. The filing was submitted five days after the transaction and appears late relative to the typical 2-business-day reporting deadline.
• Transaction type/code: Grant/Award (derivative).
• Amount: 51,000 shares reported at $0.00 (no cash exchanged at grant).
• Shares owned after transaction: Not specified in this filing.
• Footnote (vesting): The option vests in twelve substantially equal monthly installments over one year starting June 17, 2026. Any remaining unvested portion will vest the day before the next annual meeting, subject to continued service.

Context
This is a standard equity compensation grant to a director. As a derivative award, it must vest before it can be exercised or converted to tradable shares; there was no immediate exercise or sale disclosed. Such grants align management/director incentives with shareholders but do not, by themselves, indicate buying or selling sentiment.